NCT06313047View on ClinicalTrials.gov

Pharmacogenetic of Doxorubicin in HCC.

CompletedOBSERVATIONAL
Enrollment

81

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 15, 2023

Study Completion Date

December 30, 2023

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Doxorubicin

each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results.

Trial Locations (1)

Unknown

King Abdullah bin Abdulaziz University Hospital, Riyadh

All Listed Sponsors
collaborator

King Saud Bin Abdulaziz University for Health Sciences

OTHER

collaborator

King Abdulaziz University

OTHER

lead

Rehab Werida

OTHER

NCT06313047 - Pharmacogenetic of Doxorubicin in HCC. | Biotech Hunter | Biotech Hunter